FOXM1 and small cell lung carcinoma: Investigating the targeting potential of FOXM1 in SCLC for developing promising therapeutic modalities may help improve survival and quality of life of patients; therefore, we tested FOXM1 inhibitors (FOXM1i) using multiple in vitro and in vivo models of SCLC.